Analysis of invasive lobular carcinoma (ILC) of the breast from a letrozole treatment trial revealed that tumors from non-responders exhibited increased SREBP1 expression compared to responders, connecting SREBP1 to endocrine resistance development [105]. Here, SREBF1 is linked to invasive lobular breast carcinoma.